Moore Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Moore Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-140,000	Closed	-$6.27M	–	830
2025 Q4	$6.27M	Hold	140,000	–	–	0.09%	216
2025 Q3	$5.62M	Buy	140,000 +50,000	+56%	+$1.76M	0.08%	219
2025 Q2	$2.82M	Buy	90,000 +35,000	+64%	+$1.14M	0.04%	282
2025 Q1	$1.85M	Hold	55,000	–	–	0.04%	273
2024 Q4	$2.16M	Hold	55,000	–	–	0.02%	318
2024 Q3	$2.17M	Hold	55,000	–	–	0.04%	299
2024 Q2	$2.14M	Hold	55,000	–	–	0.04%	266
2024 Q1	$2.37M	Sell	55,000 -10,000	-15%	-$460K	0.04%	253
2023 Q4	$2.99M	Buy	+65,000	New	+$2.3M	0.05%	196
2023 Q2	–	Sell	-34,417	Closed	-$1.23M	–	607
2023 Q1	$1.23M	Sell	34,417 -95,000	-73%	-$3.51M	0.03%	278
2022 Q4	$5.1M	Buy	129,417 +26,440	+26%	+$963K	0.12%	144
2022 Q3	$3.72M	Sell	102,977 -69,094	-40%	-$2.48M	0.09%	258
2022 Q2	$5.23M	Buy	172,071 +143,392	+500%	+$4.34M	0.14%	156
2022 Q1	$877K	Buy	+28,679	New	+$859K	0.02%	439
2020 Q1	–	Sell	-50,000	Closed	-$656K	–	278
2019 Q4	$656K	Hold	50,000	–	–	0.02%	214
2019 Q3	$451K	Hold	50,000	–	–	0.02%	258
2019 Q2	$493K	Hold	50,000	–	–	0.01%	270
2019 Q1	$508K	Hold	50,000	–	–	0.02%	255
2018 Q4	$316K	Buy	50,000 +35,000	+233%	+$311K	0.01%	204
2018 Q3	$198K	Buy	+15,000	New	+$174K	﹤0.01%	273

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's XENE Position: Q1 2026 in Review

Moore Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 140,000 shares — an estimated $6.27M sold.

Moore Capital Management first reported a position in XENE in Q3 2018 and held it in 20 quarters. The position peaked at $6.27M in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Moore Capital Management reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 140,000 Xenon Pharmaceuticals shares in Q1 2026, an estimated $6.27M.
Moore Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 20 quarters.
Moore Capital Management's Xenon Pharmaceuticals position peaked at $6.27M in Q4 2025.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.